Intravenous (IV) Hydration Therapy Market By Service (Immune boosters, Energy boosters, Skin care, Migraine, Others), By Component (Medicated, Non-medicated) By End user (Hospital & clinics, Wellness centers & spas, Home healthcare, Others) : Global Oppor
Description
Intravenous (IV) Hydration Therapy Market By Service (Immune boosters, Energy boosters, Skin care, Migraine, Others), By Component (Medicated, Non-medicated) By End user (Hospital & clinics, Wellness centers & spas, Home healthcare, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Intravenous (IV) Hydration Therapy Market
The intravenous (IV) hydration therapy market was valued at $2.3 billion in 2023 and is projected to reach $4.9 billion by 2033, growing at a CAGR of 7.8% from 2024 to 2033.
Intravenous (IV) hydration therapy is the medical procedure in which medications, fluids, vitamins, and electrolytes are infused directly into the bloodstream through a vein. The therapy is a highly effective procedure as it ensures efficient and quick replenishment of essential fluids and nutrients lost due to dehydration. Dehydration is the excessive loss of fluids from the body caused by some illness, excessive alcohol consumption, or intense physical activity. The treatment is applicable in diverse medical settings for the management of chronic conditions, preoperative & postoperative care, and to cure patients with severe infections or gastrointestinal problems.
One of the key drivers of the intravenous (IV) hydration therapy market is increase in uptight lifestyle among individuals with high stress levels. A stressed lifestyle is one of the most common reasons for rising dehydration among individuals. In addition, the geriatric population is growing exponentially across the globe, who are highly susceptible to ailments and hospitalization. This boosts the demand for IV hydration therapy, thus augmenting the market growth. In recent times, the administration of IV therapy as a part of self-care routine or rejuvenation is trending, particularly among celebrities. Moreover, specialized centers called “hydration bars” are being established for people to receive therapy as a form of relaxation.
However, the availability of other alternatives for hydration therapy, such as the oral rehydration solutions restrain the development of the market. Furthermore, the shortage of dedicated medical facilities and well-trained staff, particularly in rural areas, presents challenges for the expansion of the market. On the contrary, advancements in technology and modifications in the conventional formulations administered during treatment are presenting lucrative opportunities for market growth. For instance, personalized solutions are being developed according to the requirements of every individual, hence aiding them to achieve their health goal.
Segment Review
The intravenous (IV) hydration therapy market is segmented into service, component, end user, and region. On the basis of service, the market is divided into immune boosters, energy boosters, skin care, migraine, and others. By component, it is bifurcated into medicated and non-medicated. As per end user, it is categorized into hospital & clinics, wellness centers & spas, home healthcare, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of service, the immune boosters segment dominates the market.
By component, the medicated segmented experiences significant demand in the market.
As per end user, the hospital & clinics segment acquires a high share of the market.
Region wise, North America leads the market.
Competition Analysis
The major players operating in the global intravenous (IV) hydration therapy market include Davita, Nikkiso Co. Ltd., Core IV Therapy, LLC, Cryojuvenate UK Ltd., B. Braun Medical Inc., Otsuka Pharmaceutical Co., Ltd., NexGen Health, JW Life Science Corporation, Amanta Healthcare Limited., and Baxter International Inc. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.
Key Market Segments
By Service
Immune boosters
Energy boosters
Skin care
Migraine
Others
By Component
Medicated
Non-medicated
By End User
Hospital clinics
Wellness centers spas
Home healthcare
Others
By Region
North America
U.S.
Canada
Mexico
Europe
France
Germany
Italy
Spain
UK
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA
Key Market Players
Davita
Nikkiso Co. Ltd.
Core IV Therapy, LLC
Cryojuvenate UK Ltd.
B. Braun Medical Inc.
Otsuka Pharmaceutical Co., Ltd.
NexGen Health
JW Life Science Corporation
Amanta Healthcare Limited.
Baxter International Inc.
Table of Contents
220 Pages
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.5. Market Dynamics
- 3.5.1. Drivers
- 3.5.2. Restraints
- 3.5.3. Opportunities
- CHAPTER 4: INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY SERVICE
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Service
- 4.2. Immune Boosters
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Energy Boosters
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Skin Care
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
- 4.5. Migraine
- 4.5.1. Key Market Trends, Growth Factors and Opportunities
- 4.5.2. Market Size and Forecast, By Region
- 4.5.3. Market Share Analysis, By Country
- 4.6. Others
- 4.6.1. Key Market Trends, Growth Factors and Opportunities
- 4.6.2. Market Size and Forecast, By Region
- 4.6.3. Market Share Analysis, By Country
- CHAPTER 5: INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY COMPONENT
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Component
- 5.2. Medicated
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Non-medicated
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- CHAPTER 6: INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY END USER
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By End User
- 6.2. Hospital Clinics
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Wellness Centers Spas
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Home Healthcare
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
- 6.5. Others
- 6.5.1. Key Market Trends, Growth Factors and Opportunities
- 6.5.2. Market Size and Forecast, By Region
- 6.5.3. Market Share Analysis, By Country
- CHAPTER 7: INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY REGION
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Service
- 7.2.3. Market Size and Forecast, By Component
- 7.2.4. Market Size and Forecast, By End User
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Intravenous (IV) Hydration Therapy Market
- 7.2.6.1. Market Size and Forecast, By Service
- 7.2.6.2. Market Size and Forecast, By Component
- 7.2.6.3. Market Size and Forecast, By End User
- 7.2.7. Canada Intravenous (IV) Hydration Therapy Market
- 7.2.7.1. Market Size and Forecast, By Service
- 7.2.7.2. Market Size and Forecast, By Component
- 7.2.7.3. Market Size and Forecast, By End User
- 7.2.8. Mexico Intravenous (IV) Hydration Therapy Market
- 7.2.8.1. Market Size and Forecast, By Service
- 7.2.8.2. Market Size and Forecast, By Component
- 7.2.8.3. Market Size and Forecast, By End User
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Service
- 7.3.3. Market Size and Forecast, By Component
- 7.3.4. Market Size and Forecast, By End User
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. France Intravenous (IV) Hydration Therapy Market
- 7.3.6.1. Market Size and Forecast, By Service
- 7.3.6.2. Market Size and Forecast, By Component
- 7.3.6.3. Market Size and Forecast, By End User
- 7.3.7. Germany Intravenous (IV) Hydration Therapy Market
- 7.3.7.1. Market Size and Forecast, By Service
- 7.3.7.2. Market Size and Forecast, By Component
- 7.3.7.3. Market Size and Forecast, By End User
- 7.3.8. Italy Intravenous (IV) Hydration Therapy Market
- 7.3.8.1. Market Size and Forecast, By Service
- 7.3.8.2. Market Size and Forecast, By Component
- 7.3.8.3. Market Size and Forecast, By End User
- 7.3.9. Spain Intravenous (IV) Hydration Therapy Market
- 7.3.9.1. Market Size and Forecast, By Service
- 7.3.9.2. Market Size and Forecast, By Component
- 7.3.9.3. Market Size and Forecast, By End User
- 7.3.10. UK Intravenous (IV) Hydration Therapy Market
- 7.3.10.1. Market Size and Forecast, By Service
- 7.3.10.2. Market Size and Forecast, By Component
- 7.3.10.3. Market Size and Forecast, By End User
- 7.3.11. Rest Of Europe Intravenous (IV) Hydration Therapy Market
- 7.3.11.1. Market Size and Forecast, By Service
- 7.3.11.2. Market Size and Forecast, By Component
- 7.3.11.3. Market Size and Forecast, By End User
- 7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Service
- 7.4.3. Market Size and Forecast, By Component
- 7.4.4. Market Size and Forecast, By End User
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. China Intravenous (IV) Hydration Therapy Market
- 7.4.6.1. Market Size and Forecast, By Service
- 7.4.6.2. Market Size and Forecast, By Component
- 7.4.6.3. Market Size and Forecast, By End User
- 7.4.7. Japan Intravenous (IV) Hydration Therapy Market
- 7.4.7.1. Market Size and Forecast, By Service
- 7.4.7.2. Market Size and Forecast, By Component
- 7.4.7.3. Market Size and Forecast, By End User
- 7.4.8. India Intravenous (IV) Hydration Therapy Market
- 7.4.8.1. Market Size and Forecast, By Service
- 7.4.8.2. Market Size and Forecast, By Component
- 7.4.8.3. Market Size and Forecast, By End User
- 7.4.9. South Korea Intravenous (IV) Hydration Therapy Market
- 7.4.9.1. Market Size and Forecast, By Service
- 7.4.9.2. Market Size and Forecast, By Component
- 7.4.9.3. Market Size and Forecast, By End User
- 7.4.10. Australia Intravenous (IV) Hydration Therapy Market
- 7.4.10.1. Market Size and Forecast, By Service
- 7.4.10.2. Market Size and Forecast, By Component
- 7.4.10.3. Market Size and Forecast, By End User
- 7.4.11. Rest of Asia-Pacific Intravenous (IV) Hydration Therapy Market
- 7.4.11.1. Market Size and Forecast, By Service
- 7.4.11.2. Market Size and Forecast, By Component
- 7.4.11.3. Market Size and Forecast, By End User
- 7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Service
- 7.5.3. Market Size and Forecast, By Component
- 7.5.4. Market Size and Forecast, By End User
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Intravenous (IV) Hydration Therapy Market
- 7.5.6.1. Market Size and Forecast, By Service
- 7.5.6.2. Market Size and Forecast, By Component
- 7.5.6.3. Market Size and Forecast, By End User
- 7.5.7. South Africa Intravenous (IV) Hydration Therapy Market
- 7.5.7.1. Market Size and Forecast, By Service
- 7.5.7.2. Market Size and Forecast, By Component
- 7.5.7.3. Market Size and Forecast, By End User
- 7.5.8. Saudi Arabia Intravenous (IV) Hydration Therapy Market
- 7.5.8.1. Market Size and Forecast, By Service
- 7.5.8.2. Market Size and Forecast, By Component
- 7.5.8.3. Market Size and Forecast, By End User
- 7.5.9. Rest of LAMEA Intravenous (IV) Hydration Therapy Market
- 7.5.9.1. Market Size and Forecast, By Service
- 7.5.9.2. Market Size and Forecast, By Component
- 7.5.9.3. Market Size and Forecast, By End User
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. Davita
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
- 9.2. Nikkiso Co. Ltd.
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. Core IV Therapy, LLC
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
- 9.4. Cryojuvenate UK Ltd.
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. B. Braun Medical Inc.
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
- 9.6. Otsuka Pharmaceutical Co., Ltd.
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
- 9.7. NexGen Health
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. JW Life Science Corporation
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
- 9.9. Amanta Healthcare Limited.
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. Baxter International Inc.?
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments
- TABLE 1. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 2. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR IMMUNE BOOSTERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 3. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR ENERGY BOOSTERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 4. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR SKIN CARE, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 5. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR MIGRAINE, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 6. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 7. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 8. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR MEDICATED, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 9. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR NON-MEDICATED, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 10. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 11. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR HOSPITAL CLINICS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 12. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR WELLNESS CENTERS SPAS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 13. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR HOME HEALTHCARE, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 14. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 15. INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 16. NORTH AMERICA INTRAVENOUS (IV) HYDRATION THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 17. NORTH AMERICA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 18. NORTH AMERICA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 19. NORTH AMERICA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 20. U.S. INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 21. U.S. INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 22. U.S. INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 23. CANADA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 24. CANADA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 25. CANADA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 26. MEXICO INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 27. MEXICO INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 28. MEXICO INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 29. EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 30. EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 31. EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 32. EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 33. FRANCE INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 34. FRANCE INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 35. FRANCE INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 36. GERMANY INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 37. GERMANY INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 38. GERMANY INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 39. ITALY INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 40. ITALY INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 41. ITALY INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 42. SPAIN INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 43. SPAIN INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 44. SPAIN INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 45. UK INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 46. UK INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 47. UK INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 48. REST OF EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 49. REST OF EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 50. REST OF EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 51. ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 52. ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 53. ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 54. ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 55. CHINA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 56. CHINA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 57. CHINA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 58. JAPAN INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 59. JAPAN INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 60. JAPAN INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 61. INDIA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 62. INDIA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 63. INDIA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 64. SOUTH KOREA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 65. SOUTH KOREA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 66. SOUTH KOREA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 67. AUSTRALIA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 68. AUSTRALIA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 69. AUSTRALIA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 70. REST OF ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 71. REST OF ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 72. REST OF ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 73. LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 74. LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 75. LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 76. LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 77. BRAZIL INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 78. BRAZIL INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 79. BRAZIL INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 80. SOUTH AFRICA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 81. SOUTH AFRICA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 82. SOUTH AFRICA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 83. SAUDI ARABIA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 84. SAUDI ARABIA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 85. SAUDI ARABIA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 86. REST OF LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
- TABLE 87. REST OF LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
- TABLE 88. REST OF LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 89. DAVITA: KEY EXECUTIVES
- TABLE 90. DAVITA: COMPANY SNAPSHOT
- TABLE 91. DAVITA: OPERATING SEGMENTS
- TABLE 92. DAVITA: PRODUCT PORTFOLIO
- TABLE 93. DAVITA: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 94. NIKKISO CO. LTD.: KEY EXECUTIVES
- TABLE 95. NIKKISO CO. LTD.: COMPANY SNAPSHOT
- TABLE 96. NIKKISO CO. LTD.: OPERATING SEGMENTS
- TABLE 97. NIKKISO CO. LTD.: PRODUCT PORTFOLIO
- TABLE 98. NIKKISO CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 99. CORE IV THERAPY, LLC: KEY EXECUTIVES
- TABLE 100. CORE IV THERAPY, LLC: COMPANY SNAPSHOT
- TABLE 101. CORE IV THERAPY, LLC: OPERATING SEGMENTS
- TABLE 102. CORE IV THERAPY, LLC: PRODUCT PORTFOLIO
- TABLE 103. CORE IV THERAPY, LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 104. CRYOJUVENATE UK LTD.: KEY EXECUTIVES
- TABLE 105. CRYOJUVENATE UK LTD.: COMPANY SNAPSHOT
- TABLE 106. CRYOJUVENATE UK LTD.: OPERATING SEGMENTS
- TABLE 107. CRYOJUVENATE UK LTD.: PRODUCT PORTFOLIO
- TABLE 108. CRYOJUVENATE UK LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 109. B. BRAUN MEDICAL INC.: KEY EXECUTIVES
- TABLE 110. B. BRAUN MEDICAL INC.: COMPANY SNAPSHOT
- TABLE 111. B. BRAUN MEDICAL INC.: OPERATING SEGMENTS
- TABLE 112. B. BRAUN MEDICAL INC.: PRODUCT PORTFOLIO
- TABLE 113. B. BRAUN MEDICAL INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 114. OTSUKA PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
- TABLE 115. OTSUKA PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
- TABLE 116. OTSUKA PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
- TABLE 117. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
- TABLE 118. OTSUKA PHARMACEUTICAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 119. NEXGEN HEALTH: KEY EXECUTIVES
- TABLE 120. NEXGEN HEALTH: COMPANY SNAPSHOT
- TABLE 121. NEXGEN HEALTH: OPERATING SEGMENTS
- TABLE 122. NEXGEN HEALTH: PRODUCT PORTFOLIO
- TABLE 123. NEXGEN HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 124. JW LIFE SCIENCE CORPORATION: KEY EXECUTIVES
- TABLE 125. JW LIFE SCIENCE CORPORATION: COMPANY SNAPSHOT
- TABLE 126. JW LIFE SCIENCE CORPORATION: OPERATING SEGMENTS
- TABLE 127. JW LIFE SCIENCE CORPORATION: PRODUCT PORTFOLIO
- TABLE 128. JW LIFE SCIENCE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 129. AMANTA HEALTHCARE LIMITED.: KEY EXECUTIVES
- TABLE 130. AMANTA HEALTHCARE LIMITED.: COMPANY SNAPSHOT
- TABLE 131. AMANTA HEALTHCARE LIMITED.: OPERATING SEGMENTS
- TABLE 132. AMANTA HEALTHCARE LIMITED.: PRODUCT PORTFOLIO
- TABLE 133. AMANTA HEALTHCARE LIMITED.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 134. BAXTER INTERNATIONAL INC.?: KEY EXECUTIVES
- TABLE 135. BAXTER INTERNATIONAL INC.?: COMPANY SNAPSHOT
- TABLE 136. BAXTER INTERNATIONAL INC.?: OPERATING SEGMENTS
- TABLE 137. BAXTER INTERNATIONAL INC.?: PRODUCT PORTFOLIO
- TABLE 138. BAXTER INTERNATIONAL INC.?: KEY STRATEGIC MOVES AND DEVELOPMENTS
- FIGURE 1. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET SEGMENTATION
- FIGURE 2. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET
- FIGURE 3. SEGMENTATION INTRAVENOUS (IV) HYDRATION THERAPY MARKET
- FIGURE 4. TOP INVESTMENT POCKET IN INTRAVENOUS (IV) HYDRATION THERAPY MARKET
- FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 8. LOW THREAT OF SUBSTITUTION
- FIGURE 9. HIGH COMPETITIVE RIVALRY
- FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALINTRAVENOUS (IV) HYDRATION THERAPY MARKET
- FIGURE 11. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET SEGMENTATION, BY SERVICE
- FIGURE 12. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR IMMUNE BOOSTERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 13. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR ENERGY BOOSTERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 14. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR SKIN CARE, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 15. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR MIGRAINE, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 16. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 17. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET SEGMENTATION, BY COMPONENT
- FIGURE 18. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR MEDICATED, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 19. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR NON-MEDICATED, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 20. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET SEGMENTATION, BY END USER
- FIGURE 21. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR HOSPITAL CLINICS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 22. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR WELLNESS CENTERS SPAS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 23. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR HOME HEALTHCARE, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 24. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
- FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
- FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
- FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 29. COMPETITIVE DASHBOARD
- FIGURE 30. COMPETITIVE HEATMAP: INTRAVENOUS (IV) HYDRATION THERAPY MARKET
- FIGURE 31. TOP PLAYER POSITIONING, 2023
- FIGURE 32. DAVITA: NET SALES, 2021-2023 ($BILLION)
- FIGURE 33. DAVITA: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 34. DAVITA: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 35. NIKKISO CO. LTD.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 36. NIKKISO CO. LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 37. NIKKISO CO. LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 38. CORE IV THERAPY, LLC: NET SALES, 2021-2023 ($BILLION)
- FIGURE 39. CORE IV THERAPY, LLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 40. CORE IV THERAPY, LLC: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 41. CRYOJUVENATE UK LTD.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 42. CRYOJUVENATE UK LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 43. CRYOJUVENATE UK LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 44. B. BRAUN MEDICAL INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 45. B. BRAUN MEDICAL INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 46. B. BRAUN MEDICAL INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 47. OTSUKA PHARMACEUTICAL CO., LTD.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 48. OTSUKA PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 49. OTSUKA PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 50. NEXGEN HEALTH: NET SALES, 2021-2023 ($BILLION)
- FIGURE 51. NEXGEN HEALTH: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 52. NEXGEN HEALTH: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 53. JW LIFE SCIENCE CORPORATION: NET SALES, 2021-2023 ($BILLION)
- FIGURE 54. JW LIFE SCIENCE CORPORATION: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 55. JW LIFE SCIENCE CORPORATION: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 56. AMANTA HEALTHCARE LIMITED.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 57. AMANTA HEALTHCARE LIMITED.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 58. AMANTA HEALTHCARE LIMITED.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 59. BAXTER INTERNATIONAL INC.?: NET SALES, 2021-2023 ($BILLION)
- FIGURE 60. BAXTER INTERNATIONAL INC.?: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 61. BAXTER INTERNATIONAL INC.?: REVENUE SHARE, BY REGION, 2023 (%)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
